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Summary
Objectives: Curcumin (diferuloylmethane) is the principal biochemical component of the spice turmeric and has been shown to possess potent
anti-catabolic, anti-inﬂammatory and antioxidant, properties. This article aims to provide a summary of the actions of curcumin on articular
chondrocytes from the available literature with the use of a text-mining tool. We highlight both the potential beneﬁts and drawbacks of using
this chemopreventive agent for treating osteoarthritis (OA). We also explore the recent literature on the molecular mechanisms of curcumin
mediated alterations in gene expression mediated via activator protein 1 (AP-1)/nuclear factor-kappa B (NF-kB) signalling in chondrocytes,
osteoblasts and synovial ﬁbroblasts.
Methods: A computer-aided search of the PubMed/Medline database aided by a text-mining tool to interrogate the ResNet Mammalian
database 6.0.
Results: Recent work has shown that curcumin protects human chondrocytes from the catabolic actions of interleukin-1 beta (IL-1b) including
matrix metalloproteinase (MMP)-3 up-regulation, inhibition of collagen type II and down-regulation of b1-integrin expression. Curcumin blocks
IL-1b-induced proteoglycan degradation, AP-1/NF-kB signalling, chondrocyte apoptosis and activation of caspase-3.
Conclusions: The available data from published in vitro and in vivo studies suggest that curcumin may be a beneﬁcial complementary treat-
ment for OA in humans and companion animals. Nevertheless, before initiating extensive clinical trials, more basic research is required to
improve its solubility, absorption and bioavailability and gain additional information about its safety and efﬁcacy in different species. Once
these obstacles have been overcome, curcumin and structurally related biochemicals may become safer and more suitable nutraceutical
alternatives to the non-steroidal anti-inﬂammatory drugs that are currently used for the treatment of OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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It is now generally accepted that osteoarthritis (OA) is not
only the ﬁnal common pathway for aging and injuries of
the joint, but it is also an active joint disease with a promi-
nent inﬂammatory component. As medical advances
lengthen average life expectancy, OA will become a larger
public health problem e not only because it is a manifesta-
tion of aging but because it usually takes many years to
reach clinical relevance. OA is already one of the ten
most disabling diseases in industrialized countries. OA isaThese authors contributed equally to this paper.
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141rare in people under 40 but becomes more common with
age e most people over 65 years of age show some radio-
graphic evidence of OA in at least one or more joints. OA is
the most frequent cause of physical disability among older
adults globally. More than 8 million people in the UK and
over 20 million Americans are estimated to have OA.b It is
also anticipated that by the year 2030, 20% of adults will
have developed OA in Western Europe and North America.
OA is not only a common problem among the elderly popu-
lation, but also it is becoming more widespread among
younger people. In the United States, rheumatoid arthritis
(RA) and OA combined affect as many as 46 million people.
This amounted to a healthcare cost of over $128 billion in
2003.c This huge ﬁnancial burden emphasizes the acute
need for new and more effective treatments for articularbhttp://www.niams.nih.gov/.
chttp://www.arthritis.org/.
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modifying drugs or treatments for OA. Existing pharmaceu-
ticals include analgesics, steroids and non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) which only treat the symptoms
of OA by reducing pain and inﬂammation. Therefore, OA
represents a major opportunity for research innovation in
the development and testing of new nutraceutical therapies.
In this concise review article we explore the anti-inﬂam-
matory properties of the turmeric derived polyphenol curcu-
min and its nutritional biochemistry in the context of its
potential for treating OA patients. Curcumin, also known
as diferuloylmethane (Fig. 1), is the best-characterized
chemopreventive agent extracted from the roots of Cur-
cuma longa (Turmeric). Curcumin possesses potent anti-
oxidative, anti-inﬂammatory, anti-septic and anti-cancer
properties. Curcumin has been described as an anti-inﬂam-
matory agent1. It has long been used as an anti-inﬂamma-
tory treatment in traditional Chinese and Ayurvedic
medicine2. Since OA and related osteoarticular conditions
of synovial joints are characterized by inﬂammation, a better
understanding of the biochemistry of curcumin and its
biological actions in joint tissues may facilitate the develop-
ment of clinically safe, orally administered therapeutic
agents for treating joint diseases.Methods
The review results of a computer-aided search of the PubMed/Medline for
the period 1977 through September 2009 [Keywords: turmeric, curcumin,
cartilage, bone, synovial membrane, inﬂammation, OA, arthritis]. Four
reviewers (YH, AM, AC and MM) selected the in vitro and in vivo studies
included in this review. To aid the traditional literature search for this review,
a text-mining tool was employed to establish relationships between important
protein molecules, biological processes and pathways in chondrocytes. The
text-mining was performed by DA and EML. The ResNet Mammalian data-
base 6.0 within Pathway Studio (Ariadne Genomics, Rockville, US) con-
sists of entities (for example, a protein, a cellular process or a disease
process) and predeﬁned functional relations that have been reported
between these entities (for example, regulation, binding, expression). These
relations are derived by automated text-mining of scientiﬁc literature from
PubMed abstracts and 47 full text journals using human, rat and mouse-
based data3. The output can be displayed and explored through a visual
and tabular interface. To identify proteins, small molecules, cell processes
and diseases associated with curcumin relevant to this review, the ResNet
database (updated October 2008) was searched using the term ‘‘curcumin’’.
The introduction and discussion sections were collectively written by all the
authors.
All the experimental papers carried out by the authors and reviewed
herein were performed with commercially available research grade curcumi-
noids containing at least 80% of curcumin.ResultsCONVENTIONAL LITERATURE REVIEWTurmeric: a major component of Indian, Chinese,
Middle Eastern and ayurvedic herbal medicine
Turmeric is an ancient spice and a traditional remedy that
has been widely used as a medicine, condiment andH3CO
OH
O OH
OCH3
OH
Fig. 1. The chemical structure of curcumin. Chemical names: difer-
uloylmethane or 1,7-bis (40-hydroxy-30-methoxyphenyl)-1,6-hepta-
diene-3,5-dione.ﬂavoring. It has been used for centuries to treat indigestion
and many other ailments in the East. The use of turmeric in
the Indian subcontinent dates back nearly 4000 years, to
the Vedic culture in India, when turmeric was the principal
spice and also held religious importance. In modern India,
turmeric is added to most meat and vegetarian dishes,
predominantly curries. Turmeric also features in Arabic, He-
brew, Turkish and Persian culinary traditions. Turmeric was
only considered as culinary spice in many other parts of the
world until the early 1970s and mid 1980s, when laboratory
researchers discovered anti-inﬂammatory compounds
called curcuminoids in the spice1,4,5. The most important
of these compounds and the most intensively studied by
far, is curcumin. Turmeric contains approximately 5% cur-
cumin, which is the main biologically active phytochemical
compound6. It is extracted and investigated for its range
of health-related and disease-preventing medicinal
properties.
Curcumin and other curcuminoids
Curcumin is the principal curcuminoid component of tur-
meric. The other major curcuminoids are demethoxycurcu-
min and bis-demethoxycurcumin7. Curcumin can exist in
at least two tautomeric forms, keto and enol. Early studies
showed that curcumin exists predominantly as a ketoeenol
tautomer. The enol form is more energetically stable in the
solid phase and in solution. More recent Nuclear Magnetic
Resonance (NMR) work has demonstrated that curcumin
exists in solution as ketoeenol tautomers8. Further
research is required to determine the fate of curcumin and
other curcuminoids as they are absorbed across the
intestine and chemically modiﬁed by the liver in laboratory
rodents, other animal models and human subjects.
Nutritional biochemistry of curcumin: absorption,
metabolism and bioavailability in vivo
There are two major problems associated with the metab-
olism and bioavailability of curcumin. The bioavailability of
naturally occurring curcumin is low e the absorption and
metabolism of the molecule in the gastrointestinal system
results in the rapid loss of its unique properties in vivo.
Also, when curcumin is ingested orally, very little may actu-
ally reach the systemic circulation. Researchers have vigor-
ously debated what ‘absorption’ actually constitutes e in the
context of this paper ‘absorption’ correlates with systemic
bioavailability in serum. Oral clinical trials in human subjects
have demonstrated that the systemic bioavailability of orally
administered curcumin is relatively low9. Curcumin is rapidly
converted to curcumin glucuronides and curcumin sulfates
or reduced to hexahydrocurcumin in the intestine and the
liver10. Metabolic derivatives of curcumin do not possess
the same biological activity as the original compound. In
one study, conjugated or reduced metabolites of curcumin
were less effective inhibitors of prostaglandine E2 (PGE2)
production in cultured human colon cells than curcumin it-
self11. The serum concentration of curcumin peaks 1e2 h
after an oral dose in human subjects with peak serum con-
centrations of 0.5, 0.6 and 1.8 mM at massive doses of 4, 6
and 8 g/day, respectively12. More recently, clinical trials
have found that plasma curcumin, curcumin sulfate and cur-
cumin glucuronide concentrations were in the range of
10 nM (0.01 mM) 1 h after a large 3.6 g dose of oral curcu-
min13. Curcumin and its glucuronidated and sulfated metab-
olites were also measured in urine at a dose of 3.6 g/day14.
Curcumin and its metabolites could not be detected in
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dence that orally administered curcumin accumulates in
gastrointestinal tissues. Colorectal cancer patients adminis-
tered 3.6 g/day of curcumin orally for 7 days prior to sur-
gery, have detectable curcumin levels in both malignant
and normal colorectal tissue15. In contrast, curcumin was
not detected in the liver tissue of patients with liver metas-
tases of colorectal cancer after the same dose of oral curcu-
min suggesting that oral curcumin administration may not
effectively deliver curcumin to tissues outside the gastroin-
testinal tract16.
Interestingly, if curcumin is dissolved in oil before inges-
tion, it might bypass some of the intestinal metabolic en-
zymes that are thought to modify its structure. It is thought
to be absorbed directly into the chylomicrons and subse-
quently, the lymphatic system, which bypasses the liver in
the ‘ﬁrst pass phenomenon’17. Numerous other approaches
have been undertaken to improve the bioavailability of cur-
cumin. These include, ﬁrstly, the use of adjuvant like piper-
ine which is an inhibitor of hepatic and intestinal
glucuronidation18; secondly, the use of liposomal curcu-
min19; thirdly, polymeric nanoparticle-encapsulated curcu-
min called ‘‘nanocurcumin’’20; fourthly, the use of curcumin
phospholipid complex21; ﬁfthly, by the use of self micro-
emulsifying drug delivery systems22; and lastly, complexed
with cyclodextrin23.
Solubility of curcumin in vitro
Curcumin is insoluble in water and other aqueous solu-
tions, thus in order to get curcumin into suspension, it
must be dissolved in organic solvents such as ethanol,
dimethyl sulfoxide (DMSO), acetone or dimethyl formami-
de24e26. The majority of in vitro studies performed by the
authors and many other investigators have been performed
with curcumin dissolved in DMSO. In our own experiments,
the experimental controls always contain equivalent con-
centrations of DMSO. Curcumin solubilized in this manner
for in vitro testing must be gradually introduced into culture
medium, else it precipitates out of solution. The half life of
curcumin in solution can vary from minutes to 6 h depend-
ing on variables such as pH, temperature and media27e29.
These factors may inﬂuence the efﬁcacy of curcumin in vitro
and must be considered when extrapolating information
from these studies.
Apoptotic, anti-apoptotic and anti-proliferative activity
of curcumin
Most of the papers that report apoptotic, anti-apoptotic
and anti-proliferative effects of curcumin have been pub-
lished in the cancer literature. It is therefore inappropriate
to cite these papers in a review that focuses on chondro-
cytes, cartilage and OA. Curcumin at concentrations up to
10 mM has been shown to have both anti-proliferative and
apoptotic effects on synoviocytes. Curcumin used in the
concentration range of 10e50 mM has been shown to
dose-dependently decrease cell viability [estimated by tet-
razolium salt reduction (MTT) assay] in cultured synovio-
cytes isolated from normal synovium30e32. In addition,
curcumin (20 mM) has been shown to enhance celecoxib’s
apoptotic effects on synovial cells from OA joints, whereas
curcumin added alone had no apoptotic effect32. The rele-
vance of this inhibitory effect on cell growth in OA is that
synovial ﬁbroblasts secrete mediators of inﬂammation and
joint destruction and are recognized as important factors
in the pathogenesis of OA. Therefore, induction ofapoptosis of these cells to induce long-term remission is
an attractive therapeutic goal. However, the curcumin con-
centration needed to induce cell apoptosis is at least three
times more elevated than the Cmax recorded in plasma
after oral administration17. One possible solution to this
problem could be intra-articular injection of high doses of
curcumin. However, the safety implications of this approach
will need to be investigated.
In cultured chondrocytes, the effect of curcumin on cell vi-
ability depends on the culture system used. Using the trans-
formed chondrocyte cell line C28/I2, Toegel and colleagues
observed a cytotoxic effect at the concentration of 50 mM33.
In primary equine chondrocytes, we have not observed any
cytotoxic effects at concentration below 12 mM (unpublished
observations). The effects of different concentrations of on
the viability of chondrocytes in equine cartilage explants
in situ is currently under investigation in our laboratories.
It would be valid to note that these concentrations are
super-physiological and will not be achieved in vivo.
We have recently tested the hypothesis that curcumin
protects human chondrocytes from the cellular and morpho-
logical alterations induced by interleukin-1 beta (IL-1b). We
investigated the in vitro effects of curcumin on apoptotic sig-
nalling proteins in IL-1b-stimulated human chondrocytes.
Human articular chondrocytes were pre-treated with
10 ng/ml IL-1b alone for 30 min before being co-treated
with IL-1b and 50 mM curcumin for 5, 15 or 30 min, respec-
tively. The production of activated caspase-3, a marker of
apoptosis marker was analyzed by immunohistochemistry,
immunoelectron microscopy and immunoblotting. Trans-
mission electron microscopy of chondrocytes stimulated
with IL-1b revealed early degenerative changes, which
were reversed by curcumin co-treatment. Additionally, cur-
cumin antagonized IL-1b-induced caspase-3 activation in
a time-dependent manner34. These studies have clearly
demonstrated that curcumin exerts anti-apoptotic effects
on IL-1b-stimulated human articular chondrocytes.
Antioxidant activity of curcumin
The degradation of articular cartilage in OA results from
a combination of inappropriate mechanical stresses on
joints with instability, inﬂammatory mediators and biochem-
ical factors, mainly matrix metalloproteinases (MMPs) and
reactive oxygen species (ROS)35. The principal ROS in-
volved in the pathogenesis and progression of OA are nitric
oxide (NO), peroxynitrite (ONOO) and superoxide anion
radicals (O2)
36. These factors are not only deleterious
agents involved in cartilage degradation, but also they act
as catabolic cell signalling molecules37. The activity of
ROS is balanced by enzymatic and non-enzymatic antioxi-
dants, that act by inhibiting oxidative enzymes, scavenging
free radicals or chelating ion metals38. A number of antiox-
idant supplements or drugs with antioxidant properties have
been developed to reinforce the cellular antioxidant status.
However, so far, there is no consistent or convincing evi-
dence to support the notion that additional antioxidant
supply is efﬁcacious in relieving the symptoms of OA or pre-
venting structural changes in OA cartilage35,38,39. Although
further investigation is required to support the concept of
antioxidant therapy in the management of joint diseases,
basic research to ﬁnd new and safe scavengers of ROS
for the treatment of OA is justiﬁed.
Curcumin has been shown to be an effective scavenger
of ROS and reactive nitrogen species in vitro40,41. However,
it is still not established whether curcumin acts directly as
an antioxidant in vivo. Curcumin may function indirectly as
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zymes, such as MMP-942 or by enhancing the synthesis
of glutathione, an important intracellular antioxidant43.
Anti-inflammatory activity of curcumin
Arachidonic acid in cell membranes plays an important
role in inﬂammatory responses by generating potent chem-
ical messengers known as eicosanoids. Membrane phos-
pholipids are hydrolyzed by phospholipase A2 (PLA2),
releasing arachidonic acid, which may be metabolized by
cyclooxygenases (COX), to form prostaglandins and throm-
boxanes; or by lipoxygenases (LOX), to form leukotrienes.
Curcumin has been found to inhibit PLA2, COX-2 and
5-LOX activity in cultured cells44. Although curcumin has
been shown to inhibit the catalytic activity of the enzyme
5-LOX directly, it inhibited PLA2 by preventing its phosphor-
ylation and COX-2 mainly by inhibiting its transcription.
Nuclear factor-kappa B (NF-kB) is the transcription factor
that enhances the transcription of the COX-2 gene and
other pro-inﬂammatory genes, such as inducible nitric oxide
synthase (iNOS). Curcumin has been found to inhibit NF-
kB-dependent gene transcription in articular chondro-
cytes34,45 (see subsequent sections). Curcumin also in-
hibits the induction of COX-2 and iNOS in cell culture and
in animal studies46,47.
Anti-catabolic activities of curcumin
Studies of synovial ﬁbroblasts cultured from human RA
patients have shown that macrophage migration inhibitory
factor (MIF) up-regulates messenger RNAs encoding
MMPs, a process which is inhibited by curcumin48. Oncos-
tatin M (OSM), a member of the IL-6 superfamily of cyto-
kines, is elevated in patients with OA and, in synergy with
IL-1b, promotes cartilage degeneration by MMPs49. Curcu-
min is able to suppress IL-1b and OSM-induced MMP-1,
MMP-3, MMP-9 and MMP-13 gene expression by human
chondrocytes via inhibition of NF-kB activation and nuclear
translocation34,45,50. The following section reviews the liter-
ature that has established the importance of the curcumin/
activator protein 1 (AP-1)/NF-kB axis and the ﬁnding that
curcumin’s potent effect on cell activity is primarily through
its inhibition of the transcription factors AP-1 and NF-kB
and modiﬁcation of binding of transactivating factors.
Mechanisms of curcumin mediated alterations in
gene expression in chondrocytes, osteoblasts and
synovial fibroblasts; functional roles of the
AP-1/NF-kB signalling pathways
There is considerable interest in the use of nutrigenomics
and plant derived phytopharamaceuticals as new therapies
for various arthritic and rheumatic conditions that affect car-
tilage, bone and synovium. Inﬂammatory processes play
a fundamental role in the damage of articular tissues and
many in vitro and in vivo studies have examined the contri-
bution of components of subcellular signalling pathways to
the pathogenesis of various rheumatic diseases such as
OA and RA51. The inhibition of MMP activity by phytophar-
maceuticals such as curcumin is also thought to be medi-
ated by inhibition of subcellular signalling pathways. The
NF-kB transcription factor is intimately involved in the regu-
lation of expression of numerous genes in the setting of
inﬂammatory diseases. NF-kB is a protein complex that
controls gene transcription in almost all animal cells. It is in-
volved in cellular responses to cytokines, free radicals, andbacterial or viral antigens52. The AP-1 is a transcription fac-
tor belonging to the c-Fos, c-Jun, activating transcription
factor (ATF) and Jun dimerization protein (JDP) families
and controls a number of cellular processes including differ-
entiation, proliferation, and apoptosis. It regulates gene
expression in response to a variety of extracellular stimuli,
including cytokines and growth factors. AP-1 up-regulates
transcription of genes containing the 12-O-tetradecanoyl-
phorbol-13-acetate DNA response element (TRE;
50-TGAG/CTCA-30)53 AP-1 binds to this DNA sequence
via a leucine zipper54. The AP-1 and NF-kB transcription
factors jointly regulate many important biological and path-
ological processes. Inﬂammation, cartilage degradation,
cell proliferation, angiogenesis and pannus formation are
processes in which the role of NF-kB is prominent55.
Consequently, the identiﬁcation of inhibitors of NF-kB sig-
nalling should pave the way for the development of novel
therapeutics for the treatment of chronic joint diseases55,56.
However, the AP-1 and NF-kB transcription factors also
play crucial homeostatic roles in the normal physiology of
joints which justiﬁes further research on these signal trans-
duction pathways.
Suppression of AP-1 activation by curcumin was observed
by Huang and co-workers in mouse ﬁbroblast cells in 199157.
Their early in vitro experiments provided the molecular evi-
dence to suggest that inhibition of c-Jun/AP-1 binding to its
cognate motif by curcumin may be responsible for the inhibi-
tion of AP-1-mediated gene expression. Onodera and col-
leagues48 expanded the work done on synovial ﬁbroblasts
by showing that the up-regulation of MMP-1 and MMP-3
mRNAs in cultured synovial ﬁbroblasts derived from RA pa-
tients in response to macrophage MIF can be inhibited by
curcumin. However, the IL-1 receptor antagonist, a speciﬁc
antagonist of the IL-1 receptor failed to inhibit the transcrip-
tional regulation of these MMPs. This study led to the conclu-
sion that MIF plays an important role in joint destruction in RA
via induction of MMPs. Later studies by the same group
showed that MIF also up-regulatesMMP-13mRNA in rat cal-
varia-derived osteoblasts. The pharmacological inhibitors
genistein, herbimycin A and 4-amino-5-(4-chlorophenyl)-7-
(t-butyl)pyrazolo [3,4-d] pyrimidine signiﬁcantly suppressed
the up-regulation of MMP-13 mRNA58. The selective mito-
gen-activated protein kinase (MAPK) kinase (MEK)1/2
inhibitor PD98059 and curcumin both suppressed the
up-regulation of MMP-13 mRNA induced by MIF58.
Subsequent work by Zafarullah’s laboratory demon-
strated that the inhibition of IL-1b-stimulated MAP kinases,
AP-1 and NF-kB transcription factors down-regulates
MMP gene expression in articular chondrocytes49. Their
work was the ﬁrst to show that inhibition of Jun N-terminal
kinase (JNK), AP-1 and NF-kB by curcumin achieved
48e99% suppression of MMP-3 and 45e97% of MMP-13
in human and 8e100% (MMP-3) and 32e100% (MMP-13)
in bovine articular chondrocytes49. Their important observa-
tions also highlighted the involvement of MAPKs, AP-1 and
NF-kB transcription factors in the IL-1b induction of MMPs
in chondrocytes. Later work from the same group using pri-
mary human chondrocytes derived from OA femoral heads
or chondrosarcoma cells demonstrated that inhibitors of ex-
tracellular signal-related kinases (ERK) (U0126, PD98059,
and ERK1/2 antisense phosphorothioate oligonucleotide),
JNK (curcumin, SB203580, and SP600125), and p38
(SB203580 and SB202190) pathways down-regulate the tu-
mor necrosis factor-stimulated expression of MMP-1359.
Human wee1 kinase is a protein kinase that down-regu-
lates theM-phase promoting factor, a complex of cell division
cycle 2 (cdc2) and cyclin B kinase, which controls mitotic cell
Fig. 2. The curcumin/AP-1/NF-kB axis in inﬂammatory cell signalling responses in joint cells. This schematic illustrates the potential sites of
action of curcumin in the NF-kB signalling pathway in a typical joint cell. Curcumin (C) can prevent IkBa phosphorylation, as well as preventing
the translocation of active NF-kB into the nucleus, thereby preventing it from activating gene expression of MMPs, stimulators of MMP syn-
thesis (cytokines), inﬂammatory mediators (cytokines and COX-2) and apoptotic executioners (caspase-3).
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gulated in association with c-Fos/AP-1. Work on rheumatoid
synovial cells has shown that thewee1 kinase gene promoter
region contains an AP-1-binding motif (50-CGAGTCA-30;
-823/-817) through which wee1 kinase gene is directly trans-
activated by c-Fos/AP-160. In rheumatoid synovial cells wee1
kinase increases in conjunction with the increase of c-Fos/
AP-1 but this increase is inhibited by curcumin60.
Other studies have used osteosarcoma cells and curcu-
min as an inhibitor of AP-1 to inhibit the biological actions
of OSM and provide evidence for the activation of the
MEK/ERK and signal transducer and activator of transcrip-
tion (STAT) pathways in OSM signalling61.Recent work on IL-17 and IL-18 has shown that these cyto-
kines have the capacity to promote cartilage breakdown by
inducing MMPs, aggrecanases and growth factors in
arthritic joints. Curcumin and Bay-11-7085 have been shown
to block IL-17 signalling pathways62. Similarly curcumin has
been shown to dose-dependently abrogate the effect of
IL-18 on vascular endothelial growth factor (VEGF) produc-
tion63. Thus IL-17 and IL-18 mediated MMP, a disintegrin-
like and metalloproteinase with thrombospondin motifs
(ADAM-TS) and VEGF up-regulation may be targeted via
AP-1 and NF-kB inhibition using curcumin.
These focussed studies in joint derived cells enforce the
well-established ﬁnding from other cells and tissue that
Table I
Summary of the biological actions of curcumin on joint tissues
Cell viability
 Decreases cell viability of adherent synoviocytes
 No effect on cell viability of adherent chondrocytes, chondrocytes in alginate beads or in cartilage explants
(at concentration below 30 mM)
 Antagonizes IL-1b-induced caspase-3 activation in a time-dependent manner
Antioxidant effects
 Scavenger of reactive oxygen and nitrogen species in vitro
 Inhibits IL-1b-induced NO production by bovine and human chondrocytes and human cartilage explants
 Inhibits IL-1b-induced superoxide dismutase activity in bovine chondrocytes in monolayer
Anti-inflammatory effects
 Inhibits NF-kB-dependent gene transcription in chondrocytes
 Inhibits COX-2, but not COX-1, gene expression in IL-1b-treated bovine chondrocytes in monolayer
 Inhibits IL-6 and IL-8 gene expression by bovine and human chondrocytes
 Inhibits IL-6, IL-8 and PGE2 production by human chondrocytes and cartilage explants
Anti-catabolic effects
 Inhibits IL-1b-induced glycosaminoglycan (GAG) release from canine and human OA cartilage explants
 Decreases MMP-3 synthesis in chondrocytes in alginate beads and in human cartilage explants
 Suppresses IL-1b and OSM-induced MMP-1, MMP-3, MMP-9 and MMP-13 gene expression by human chondrocytes via inhibition of NF-
kB activation and nuclear translocation
Anabolic effects
 No effect on aggrecan production by human chondrocytes in alginate beads
 Decreases proteoglycan mRNA expression in bovine chondrocytes in monolayer
 Reverses the IL-1b-induced inhibition of type II collagen and b1-integrin gene expression in human chondrocytes
146 Y. Henrotin et al.: Biological actions of curcumin on chondrocytescurcumin’s potent effect on cell activity is achieved through
its inhibition of transcription factor AP-1 and NF-kB medi-
ated gene expression. The results of these studies are sum-
marized in Fig. 2.Potential anabolic effects of curcumin
Any anabolic effects mediated by curcumin may be attrib-
uted to its anti-catabolic effects. Direct evidence for its
involvement as a pro-anabolic compound is still lacking.
IL-1b is well known for down regulating type II collagen ex-
pression in chondrocytes; we have shown that this process
is reversed by curcumin treatment. In addition to its effects
on type II collagen expression, curcumin also reverses the
IL-1b induced down-regulation of b1 integrin64. Recently,
Jackson et al. showed that micromolar concentrations of cur-
cumin (10 mM) decreased and inhibited collagenase and
stromelysin expression in HIG-28 rabbit chondrocytes30.TEXT-MINING REVIEWText-mining as a tool for investigating inflammatory
pathways in chondrocytes
The application of advanced information retrieval
systems can assist in reviewing scientiﬁc data65. In addition
to the traditional literature search for this review, a text-min-
ing/entity relationship tool was employed as described in
the Methods section.
An initial search for curcumin across all cell types identi-
ﬁed 113 cell processes with direct relations to curcumin.The same search restricted to chondrocytes identiﬁed
only two cell processes (pathogenesis and translation).
Searching for direct relations between curcumin and pro-
tein/protein classes across all cell types reported relations
with 426 protein/protein classes. Restricting the search to
chondrocyte as a cell type, curcumin has relations with
eight proteins and three protein classes. These analyses in-
dicate that the scientiﬁc literature reporting the action of cur-
cumin in chondrocytes has been focused to comparatively
few biological processes and proteins. Based on these
analyses curcumin may have many other effects on chon-
drocyte cellular function beyond those investigated to date.
Whilst direct relations between curcumin and other enti-
ties/processes in chondrocyte retrieved limited information,
it was considered that further analysis could provide insight
into the potential inﬂuence of curcumin in chondrocyte.
Extending the search to include direct relations between
‘‘curcumin-related proteins’’ within chondrocytes and
‘‘cell processes’’ and ‘‘diseases’’ indicated the potential
range of processes and diseases related to chondrocyte
function that could be affected by the actions of curcumin.
Text-mining revealed the central roles that are played by
NF-kB, MMP-1, MMP-3, MMP-13 and caspase-3 in articular
chondrocytes and the inter-relationships between these
proteins and various processes (for example, cartilage
degeneration, arthritis, OA, bone growth, bone fracture
healing, apoptosis). The contribution of curcumin to these
processes is important as a direct relation exists between
curcumin and MMP-1, -9 and -13 as well as caspase-3,
NF-kB and STAT.
Whilst an automated text-mining search cannot replace
the expert reviewer it does support the traditional approach
147Osteoarthritis and Cartilage Vol. 18, No. 2and provides a relatively simple and rapid visual tool to aid
knowledge management, interrogating the literature in
PubMed/Medline and undertake knowledge gap analysis.
This approach has helped us sharpen our focus on inﬂam-
matory pathways that are speciﬁcally activated in chondro-
cytes in response to pro-inﬂammatory mediators and
investigate the contribution of curcumin to this area of the
literature on articular chondrocytes.
In summary, text-mining has proved to be a powerful for
interrogating the literature in PubMed. This approach has
helped us sharpen our focus on pathways that are speciﬁ-
cally activated in chondrocytes in response to pro-inﬂam-
matory mediators and investigate the contribution of
curcumin to this area of the literature on articular
chondrocytes.Conclusions and future perspectives
In modern developed countries, public concern about
synthetic drugs and their negative side effects is growing.
Consequently, there is increasing interest in natural reme-
dies, particularly those of botanical origin. Plant derived
extracts, which possess therapeutic properties, such as cur-
cumin, offer a potentially safer and cheaper alternative to
conventional drugs. Curcumin has beneﬁcial effects on
numerous cell types in vitro and has already begun clinical
trials in humans (Table I). However, the bioavailability of
curcumin and its metabolites is debatable and has raised
the question of whether these in vitro effects can be repli-
cated in vivo.
We have used text-mining and a conventional literature
search based review of the literature to summarize the re-
search that has been done in this area. Although the major-
ity of papers quoted in this review may support the scientiﬁc
rationale that curcumin beneﬁts OA patients, much more
research is needed to gain a better understanding of its
potential side effects and contra-indications associated
with long-term consumption of curcumin and curcuminoids.
This review also highlights the fact that the effects of curcu-
min on articular chondrocytes are relatively limited. How-
ever, the existing published research suggests that it may
offer considerable potential as an aid to preventing or at
least delaying the onset of OA. In fact, its anti-catabolic ef-
fects, namely reducing degradative enzyme expression and
activity, and its positive inﬂuence on anabolic gene
expression suggests that it may be a suitable adjunct to
conventional pharmaceutical therapy. Curcumin is also
a powerful inhibitor of inﬂammatory mediators, indicating
that it could be an alternative to NSAIDs. In contrast to
NSAIDs, curcumin has no gastrointestinal side effects,
and can even protect the gastric mucosa. Therefore, curcu-
min could be beneﬁcial in the management of chronic
inﬂammatory-related joint disease, including OA. However,
despite this optimistic view, it must be recognized that there
is a paucity of data regarding possible adverse effects of
curcumin at concentrations that are biologically effective
in vitro. The absence of systemic adverse effects after
oral administration of curcumin is probably the result of its
poor bioavailability and chemical modiﬁcation by the gut
and liver. Whilst some evidence exists for toxicity, at su-
per-physiological concentrations, these are unlikely to be
experienced or achieved in vivo. Nevertheless, we cannot
exclude the possibility that increasing curcumin absorption,
by chemical or natural process, could have unsuspected
deleterious effects. It is now documented that curcumin at
concentrations in excess of 50 mM shows cytotoxicity ina chondrocyte cell line33. In addition, there is no published
information about the possible side effects of the metabo-
lites of curcumin. Further work is therefore required to ad-
dress the issues of bioavailability and tissue accumulation
in order to calculate appropriate dose formulations to
assess whether curcumin can be convincingly considered
as an aid to treating OA in both human and veterinary
medicine.Conﬂict of interest and funding disclosure
The Bone and Cartilage Unit (BCRU-University of Lie`ge)
has received an educational grant to evaluate the anti-
inﬂammatory properties of a turmeric extract containing
min. 90% of curcumin. This extract is not a product proprie-
tary to bioXtract. This is a commercially available extract,
produced according to the European speciﬁcations for
food additive E100 (Commission Directive 95/45/EC of 26
July 1995 laying down speciﬁc purity criteria concerning col-
ours for use in foodstuffs). Therefore, the effects reported
by BCRU are not speciﬁc to a product commercialized by
bioXtract. Further, Prof Henrotin did not received consulting
fees to perform these in vitro investigations.Acknowledgements
This work was supported by an unrestricted grant from
BioXtract, Belgium, and by the Belgian Foundation for
Scientiﬁc Research (FNRS; grant 1.5.236.05). ALC is sup-
ported by an Industrial CASE Studentship awarded to PH
and AM from the Biotechnology and Biological Sciences
Research Council and the WALTHAM Centre for Pet Nutri-
tion (MARS). BBSRC Contract Grant Number: BBSRC/S/
M/2006/13141.References
1. Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcu-
min), a non-steroidal anti-inﬂammatory agent. J Pharm Pharmacol
1973;25:447e52.
2. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as ‘‘Curecumin’’:
from kitchen to clinic. Biochem Pharmacol 2008;75:787e809.
3. NikitinA, EgorovS,DaraseliaN,Mazo I. Pathway studioethe analysis and
navigation of molecular networks. Bioinformatics 2003;19:2155e7.
4. Srivastava R, Srimal RC. Modiﬁcation of certain inﬂammation-induced
biochemical changes by curcumin. Indian J Med Res 1985;81:
215e23.
5. Mukhopadhyay A, Basu N, Ghatak N, Gujral PK. Anti-inﬂammatory and
irritant activities of curcumin analogues in rats. Agents Actions 1982;
12:508e15.
6. Asakawa N, Tsuno M, Hattori T, Ueyama M, Shinoda A, Miyake Y, et al.
Determination of curcumin content of turmeric by high performance
liquid chromatography (author’s transl). Yakugaku Zasshi 1981;101:
374e7.
7. Zeng Y, Qiu F, Liu Y, Qu G, Yao X. Isolation and identiﬁcation of phase 1
metabolites of demethoxycurcumin in rats. Drug Metab Dispos 2007;
35:1564e73.
8. Payton F, Sandusky P, Alworth WL. NMR study of the solution structure
of curcumin. J Nat Prod 2007;70:143e6.
9. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J
Cancer 2005;41:1955e68.
10. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML,
et al. Metabolism of the cancer chemopreventive agent curcumin in
human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;
11:105e11.
11. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, Luo JL, et al. Char-
acterization of metabolites of the chemopreventive agent curcumin
in human and rat hepatocytes and in the rat in vivo, and evaluation
of their ability to inhibit phorbol ester-induced prostaglandin E2 pro-
duction. Cancer Res 2001;61:1058e64.
148 Y. Henrotin et al.: Biological actions of curcumin on chondrocytes12. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I
clinical trial of curcumin, a chemopreventive agent, in patients with
high-risk or pre-malignant lesions. Anticancer Res 2001;21:
2895e900.
13. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR,
et al. Phase I clinical trial of oral curcumin: biomarkers of systemic
activity and compliance. Clin Cancer Res 2004;10:6847e54.
14. Heath DD, Pruitt MA, Brenner DE, Begum AN, Frautschy SA, Rock CL.
Tetrahydrocurcumin in plasma and urine: quantitation by high perfor-
mance liquid chromatography. J Chromatogr B Analyt Technol Bi-
omed Life Sci 2005;824:206e12.
15. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB,
et al. Consumption of the putative chemopreventive agent curcumin
by cancer patients: assessment of curcumin levels in the colorectum
and their pharmacodynamic consequences. Cancer Epidemiol
Biomarkers Prev 2005;14:120e5.
16. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA,
et al. Detection of curcumin and its metabolites in hepatic tissue
and portal blood of patients following oral administration. Br J Cancer
2004;90:1011e5.
17. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability
of curcumin: problems and promises. Mol Pharm 2007;4:807e18.
18. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Inﬂu-
ence of piperine on the pharmacokinetics of curcumin in animals and
human volunteers. Planta Med 1998;64:353e6.
19. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro
and in vivo effects on proliferation, apoptosis, signaling, and angio-
genesis. Cancer 2005;104:1322e31.
20. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, Maitra A, et al. Poly-
meric nanoparticle-encapsulated curcumin (‘‘nanocurcumin’’):
a novel strategy for human cancer therapy. J Nanobiotechnology
2007;5:3.
21. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-
phospholipid complex: preparation, therapeutic evaluation and phar-
macokinetic study in rats. Int J Pharm 2007;330:155e63.
22. Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H, et al. Enhancement of oral ab-
sorption of curcumin by self-microemulsifying drug delivery systems.
Int J Pharm 2009;371:148e55.
23. Tomren MA, Masson M, Loftsson T, Tonnesen HH. Studies on curcumin
and curcuminoids XXXI. Symmetric and asymmetric curcuminoids:
stability, activity and complexation with cyclodextrin. Int J Pharm
2007;338:27e34.
24. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV,
Limtrakul PN. Modulation of P-glycoprotein expression and function
by curcumin in multidrug-resistant human KB cells. Biochem Pharma-
col 2002;64:573e82.
25. Gopinath D, Ahmed MR, Gomathi K, Chitra K, Sehgal PK, Jayakumar R.
Dermal wound healing processes with curcumin incorporated colla-
gen ﬁlms. Biomaterials 2004;25:1911e7.
26. Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric ox-
ide synthase gene expression by curcumin, a cancer preventive nat-
ural product with anti-inﬂammatory properties. Biochem Pharmacol
1998;55:1955e62.
27. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, et al. Stability of
curcumin in buffer solutions and characterization of its degradation
products. J Pharm Biomed Anal 1997;15:1867e76.
28. Kurien BT, Singh A, Matsumoto H, Scoﬁeld RH. Improving the solubility
and pharmacological efﬁcacy of curcumin by heat treatment. Assay
Drug Dev Technol 2007;5:567e76.
29. Tonnesen HH, Masson M, Loftsson T. Studies of curcumin and curcumi-
noids. XXVII. Cyclodextrin complexation: solubility, chemical and pho-
tochemical stability. Int J Pharm 2002;244:127e35.
30. Jackson JK, Higo T, Hunter WL, Burt HM. The antioxidants curcumin
and quercetin inhibit inﬂammatory processes associated with arthritis.
Inﬂamm Res 2006;55:168e75.
31. Thompson KH, Bohmerle K, Polishchuk E, Martins C, Toleikis P, Tse J,
et al. Complementary inhibition of synoviocyte, smooth muscle cell or
mouse lymphoma cell proliferation by a vanadyl curcumin complex
compared to curcumin alone. J Inorg Biochem 2004;98:2063e70.
32. Lev-Ari S, Strier L, Kazanov D, Elkayam O, Lichtenberg D, Caspi D,
et al. Curcumin synergistically potentiates the growth-inhibitory and
pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent
cells. Rheumatology (Oxford) 2006;45:171e7.
33. Toegel S, Wu SQ, Piana C, Unger FM, Wirth M, Goldring MB, et al.
Comparison between chondroprotective effects of glucosamine, cur-
cumin, and diacerein in IL-1beta-stimulated C-28/I2 chondrocytes.
Osteoarthritis Cartilage 2008;16:1205e12.
34. Shakibaei M, Schulze-Tanzil G, John T, Mobasheri A. Curcumin pro-
tects human chondrocytes from IL-l1beta-induced inhibition of colla-
gen type II and beta1-integrin expression and activation of caspase-
3: an immunomorphological study. Ann Anat 2005;187:487e97.
35. Henrotin Y, Kurz B. Antioxidant to treat osteoarthritis: dream or reality?
Curr Drug Targets 2007;8:347e57.36. Abramson SB. Nitric oxide in inﬂammation and pain associated with
osteoarthritis. Arthritis Res Ther 2008;10(Suppl 2):S2.
37. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species
in homeostasis and degradation of cartilage. Osteoarthritis Cartilage
2003;11:747e55.
38. Henrotin Y, Kurz B, Aigner T. Oxygen and reactive oxygen species in
cartilage degradation: friends or foes? Osteoarthritis Cartilage 2005;
13:643e54.
39. Henrotin Y, Sanchez C, Balligand M. Pharmaceutical and nutraceutical
management of canine osteoarthritis: present and future perspectives.
Vet J 2005;170:113e23.
40. Sreejayan, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm
Pharmacol 1997;49:105e7.
41. Sreejayan N, Rao MN. Free radical scavenging activity of curcuminoids.
Arzneimittelforschung 1996;46:169e71.
42. Swarnakar S, Ganguly K, Kundu P, Banerjee A, Maity P, Sharma AV.
Curcumin regulates expression and activity of matrix metalloprotei-
nases 9 and 2 during prevention and healing of indomethacin-induced
gastric ulcer. J Biol Chem 2005;280:9409e15.
43. Nishinaka T, Ichijo Y, Ito M, Kimura M, Katsuyama M, Iwata K, et al.
Curcumin activates human glutathione S-transferase P1 expression
through antioxidant response element. Toxicol Lett 2007;170:
238e47.
44. Hong J, Bose M, Ju J, Ryu JH, Chen X, Sang S, et al. Modulation of
arachidonic acid metabolism by curcumin and related beta-diketone
derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases
and 5-lipoxygenase. Carcinogenesis 2004;25:1671e9.
45. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M. Effects
of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in
interleukin-1beta-stimulated chondrocytes. Ann N Y Acad Sci 2004;
1030:578e86.
46. Brouet I, Ohshima H. Curcumin, an anti-tumour promoter and anti-in-
ﬂammatory agent, inhibits induction of nitric oxide synthase in acti-
vated macrophages. Biochem Biophys Res Commun 1995;206:
533e40.
47. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P,
Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in
rats by inhibiting the expression of NF-kappa B-dependent genes.
Am J Physiol Gastrointest Liver Physiol 2003;284:G321e7.
48. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J.
Macrophage migration inhibitory factor up-regulates expression of
matrix metalloproteinases in synovial ﬁbroblasts of rheumatoid arthri-
tis. J Biol Chem 2000;275:444e50.
49. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-
stimulated MAP kinases, activating protein-1 (AP-1) and nuclear fac-
tor kappa B (NF-kappa B) transcription factors down-regulates matrix
metalloproteinase gene expression in articular chondrocytes. Matrix
Biol 2002;21:251e62.
50. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metallo-
proteinase and tissue inhibitor of metalloproteinase-3 genes expres-
sion in chondrocytes requires Janus kinase/STAT signaling
pathway. J Immunol 2001;166:3491e8.
51. Berenbaum F. Signaling transduction: target in osteoarthritis. Curr Opin
Rheumatol 2004;16:616e22.
52. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspec-
tives. Oncogene 2006;25:6680e4.
53. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and har-
mony among siblings. J Cell Sci 2004;117:5965e73.
54. Glover JN, Harrison SC. Crystal structure of the heterodimeric bZIP
transcription factor c-Fos-c-Jun bound to DNA. Nature 1995;373:257e61.
55. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic tar-
get in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage
2006;14:839e48.
56. Roshak AK, Callahan JF, Blake SM. Small-molecule inhibitors of NF-
kappaB for the treatment of inﬂammatory joint disease. Curr Opin
Pharmacol 2002;2:316e21.
57. Huang TS, Lee SC, Lin JK. Suppression of c-Jun/AP-1 activation by an
inhibitor of tumor promotion in mouse ﬁbroblast cells. Proc Natl Acad
Sci USA 1991;88:5292e6.
58. Onodera S, Nishihira J, Iwabuchi K, Koyama Y, Yoshida K, Tanaka S,
et al. Macrophage migration inhibitory factor up-regulates matrix met-
alloproteinase-9 and -13 in rat osteoblasts. Relevance to intracellular
signaling pathways. J Biol Chem 2002;277:7865e74.
59. Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M, et al.
Induction of matrix metalloproteinase-13 gene expression by TNF-
alpha is mediated by MAP kinases, AP-1, and NF-kappaB tran-
scription factors in articular chondrocytes. Exp Cell Res 2003;288:
208e17.
60. Kawasaki H, Komai K, Nakamura M, Yamamoto E, Ouyang Z,
Nakashima T, et al. Human wee1 kinase is directly transactivated by
and increased in association with c-Fos/AP-1: rheumatoid synovial cells
overexpressing these genes go into aberrant mitosis. Oncogene 2003;
22:6839e44.
149Osteoarthritis and Cartilage Vol. 18, No. 261. Lin SK, Kok SH, Yeh FT, Kuo MY, Lin CC, Wang CC, et al. MEK/ERK
and signal transducer and activator of transcription signaling path-
ways modulate oncostatin M-stimulated CCL2 expression in human
osteoblasts through a common transcription factor. Arthritis Rheum
2004;50:785e93.
62. Sylvester J, Liacini A, Li WQ, Zafarullah M. Interleukin-17 signal trans-
duction pathways implicated in inducing matrix metalloproteinase-3,
-13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal
2004;16:469e76.
63. Cho ML, Jung YO, Moon YM, Min SY, Yoon CH, Lee SH, et al. Interleu-
kin-18 induces the production of vascular endothelial growth factor(VEGF) in rheumatoid arthritis synovial ﬁbroblasts via AP-1-depen-
dent pathways. Immunol Lett 2006;103:159e66.
64. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Sup-
pression of NF-kappaB activation by curcumin leads to inhibition of
expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in
human articular chondrocytes: implications for the treatment of osteo-
arthritis. Biochem Pharmacol 2007;73:1434e45.
65. Hettne KM, de Mos M, de Bruijn AG, Weeber M, Boyer S, van
Mulligen EM, et al. Applied information retrieval and multidisciplinary
research: new mechanistic hypotheses in complex regional pain syn-
drome. J Biomed Discov Collab 2007;2:2.
